FDA Cites Island Kinetics, Inc. d.b.a. CoValence Laboratories in 2026-07-16 Warning Letter — CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated
TL;DR
At a glance: The FDA's Center for Drug Evaluation and Research issued a warning letter (320-26-104, July 16, 2026) to Island Kinetics, Inc. d.b.a. CoValence Laboratories, Chandler, AZ, following a January 14-23, 2026 inspection documenting CGMP violations for finished pharmaceuticals. The letter identifies failures in process validation, equipment cleaning validation, and written procedures for production control; states that TreeActiv Cystic Acne Spot Treatment, Ayadara Warrior Two Acne Spot Treatment, and Skin Script Cranberry Turnover Peel are unapproved new drugs and/or misbranded; and characterizes the products as adulterated under 21 U.S.C. 351(a)(2)(B). The firm's February 12, 2026 response was deemed inadequate because it did not address batches released prior to July 2025 or provide an interim plan for distributed products pending completion of process validation.
Argus analysis
# FDA Warning Letter Analysis: Island Kinetics, Inc. d.b.a. CoValence Laboratories
Island Kinetics, Inc. d.b.a. CoValence Laboratories, a drug manufacturer in Chandler, Arizona, received a warning letter from the FDA's Center for Drug Evaluation and Research (CDER) on July 16, 2026, following an inspection conducted January 14–23, 2026. The agency identified significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. Three products—TreeActiv Cystic Acne Spot Treatment, Ayadara Warrior Two Acne Spot Treatment, and Skin Script Cranberry Turnover Peel—were cited as unapproved new drugs introduced into interstate commerce. Two products were additionally flagged as misbranded.
The violations center on 21 CFR parts 210 and 211, which establish CGMP standards for pharmaceutical manufacturing. Specifically, the company failed to validate manufacturing processes (21 CFR 211.100(a)), lacking documentation that production consistently yields products of uniform quality. The FDA also identified inadequate cleaning validation between equipment batches, risking cross-contamination. A modified water system underwent equipment changes in October 2024 without requalification, and the company's contract laboratory repeatedly reported contamination results exceeding United States Pharmacopeia specifications without adequate investigation or remediation.
Island Kinetics submitted a response to the FDA's Form 483 on February 12, 2026, but the agency found it insufficient across multiple areas. The company has not yet published a formal corrective action timeline in publicly available records. Peer compliance officers in OTC pharmaceutical manufacturing should monitor for follow-up FDA communications, potential product recalls, import alerts, or consent decrees. The company's failure to address pre-July 2025 batch distributions and lack of interim quality assurance plans suggest regulatory momentum toward enforcement beyond the warning letter stage.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Island Kinetics, Inc. d.b.a. CoValence Laboratories MARCS-CMS 726379 — July 16, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Email Return Receipt Requested Reference #: 320-26-104 Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Mr. Peter J. Vlcek Recipient Title CEO Island Kinetics, Inc. d.b.a. CoValence Laboratories 460 S. Benson Ln. Suite 1-3 Chandler , AZ 85224-5663 United States Pete@CoValence.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-104 July 16, 2026 Dear Mr. Vlcek: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Island Kinetics, Inc. d.b.a. CoValence Laboratories, FEI 3002408934, at 460 S. Benson Ln. Suite 1-3, Chandler, AZ, from January 14 to 23, 2026. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). In addition, violations were identified and documented during a review of your product labeling. Based on our review, your TreeActiv Cystic Acne Spot Treatment, Ayadara Warrior Two Acne Spot Treatment, and Skin Script Cranberry Turnover Peel drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a), 331(d). In addition, TreeActivCystic Acne Spot Treatment and Ayadara Warrior Two Acne Spot Treatment are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introducing or delivering these misbranded products for introduction into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below. We reviewed your February 12, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. During our inspection, our investigators observed specific violations including, but not limited to, the following. 1. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)). Lack of Process Validation You lacked process validation data for all your over-the-counter (OTC) drug products to demonstrate that your manufacturing process is reproducible and controlled to consistently yield drug products of uniform character and quality. For example, the inspection d…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Island Kinetics, Inc. d.b.a. CoValence Laboratories had FDA enforcement actions before?
- Yes. Argus HQ has recorded 5 total FDA actions tied to Island Kinetics, Inc. d.b.a. CoValence Laboratories: 1 warning letter, 4 recalls, and 0 approval records.
- What FDA violations was Island Kinetics, Inc. d.b.a. CoValence Laboratories cited for?
- The FDA Warning Letter to Island Kinetics, Inc. d.b.a. CoValence Laboratories (issuing office: Center for Drug Evaluation and Research (CDER)) cites: CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to Island Kinetics, Inc. d.b.a. CoValence Laboratories?
- FDA issued the letter (MARCS-CMS 726379) on 2026-07-16 and posted it publicly on fda.gov on 2026-07-21.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites Island Kinetics, Inc. d.b.a. CoValence Laboratories in 2026-07-16 Warning Letter — CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-island-kinetics-inc-d-b-a-covalence-laboratories-2026-07-16-cgmp
"FDA Cites Island Kinetics, Inc. d.b.a. CoValence Laboratories in 2026-07-16 Warning Letter — CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-island-kinetics-inc-d-b-a-covalence-laboratories-2026-07-16-cgmp.
Argus HQ Research. "FDA Cites Island Kinetics, Inc. d.b.a. CoValence Laboratories in 2026-07-16 Warning Letter — CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated." Digital Empire Holdings LLC. Accessed July 22, 2026. https://argushq.ai/fda/warning-letter/fda-wl-island-kinetics-inc-d-b-a-covalence-laboratories-2026-07-16-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_island_kinetics_inc_d_b_a_covalence_laboratories_2026_07_16_cgmp_2026,
title = {FDA Cites Island Kinetics, Inc. d.b.a. CoValence Laboratories in 2026-07-16 Warning Letter — CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-island-kinetics-inc-d-b-a-covalence-laboratories-2026-07-16-cgmp},
note = {Accessed: July 22, 2026}
}